A Feasibility Study of Co-Established Patient-Derived Subcutaneous Xenograft and Organotypic Slice Cultures in Hormone-Naive Primary Prostate Cancer Preclinical Modeling: A Single-Institution Experience
Authors:
- Valeria PecciVPValeria Pecci
- Melissa BorsaMBMelissa Borsa
- Aurora AielloAAAurora Aiello
- Sara De MartinoSMSara De Martino
- Luca CisLCLuca Cis
- Francesco PiercontiFPFrancesco Pierconti
- Domenico VaracalliDVDomenico Varacalli
- Martina BraccoMBMartina Bracco
- Cristian RipoliCristian Ripoli
- Francesco PintoFPFrancesco Pinto
- Dante RotiliDRDante Rotili
- Claudio GrassiClaudio Grassi
Open Access
Abstract
Background: Preclinical models that preserve the tumor microenvironment are critically needed in prostate cancer (PCa) research. Patient-derived xenografts (PDXs) and patient-derived Organotypic Slice Cultures (PD-OSCs) have emerged as promising in vivo and ex vivo platforms to address this gap and better mimic human tumor biology. Methods: Subcutaneous PDX models and PD-OSCs were established in parallel from fresh, primary hormone-naïve PCa patient tissues. PDX models were generated by engrafting tumor fragments into immunodeficient mice, while PD-OSCs were maintained as short-term ex vivo cultures for functional analysis. Results: A cohort of 64 PDXs and 45 PD-OSCs was generated. While first-generation PDX engraftment was successful, subsequent passaging and model expansion were extremely poor. In contrast, PD-OSCs were reliably established, maintained tissue viability, and proved to be a robust platform for functional testing, including gene expression analysis and drug sensitivity screening. Conclusions: Our findings establish both first-generation PDXs and PD-OSCs as valuable “avatar” models for translational research. However, PD-OSCs represent a more efficient and rapid platform for studying primary hormone-naïve PCa biology and evaluating treatment responses, holding significant promise as a predictive tool to guide personalized medicine.Keywords
Funding Information
- Ministero della Salute (RF-2019-12370266)
- Fondazione Italiana per la Ricerca sul Cancro (IG 2019-ID 22858)
- Italian Ministry of Education, University and Research (PRIN2022WWY7AA)
- EU funding (CN00000041 CN3 RNA)
This publication has 35 references indexed in Scilit:
- Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development2024
- Defining the challenges and opportunities for using patient‐derived models in prostate cancer researchThe Prostate, 2024
- Protocol for ex vivo culture of patient-derived tumor fragmentsSTAR Protocols, 2023
- Protocol to generate a patient derived xenograft model of acquired resistance to immunotherapy in humanized miceSTAR Protocols, 2022
- Trends in Incidence of Metastatic Prostate Cancer in the USJAMA Network Open, 2022
- Functional Organotypic Cultures of Prostate TissuesThe American Journal of Pathology, 2019
- A patient‐derived explant (PDE) model of hormone‐dependent cancerMolecular Oncology, 2018
- Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient‐derived xenograft (PDX) modelsThe Prostate, 2018
- Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell LinesCell Reports, 2017
- LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer TherapeuticsThe Prostate, 2017